Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo

No abstract is available for this paper.

• Publication year

  2006

• Venue

  FEBS Letters

• Publication date

  2006-06-26

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.febslet.2006.05.029PMID 16753151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Tau phosphorylation and aggregation in Alzheimer's disease pathology

  2006cited by this paper
• Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.

  2005cited by this paper
• Tau, tangles, and Alzheimer's disease.

  2005cited by this paper
• Tau pathology in Alzheimer disease and other tauopathies.

  2005cited by this paper
• Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease

  2004cited by this paper
• A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads

  2004cited by this paper
• Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases.

  2004cited by this paper
• Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423

  2004cited by this paper
• DC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitope

  2003cited by this paper
• Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease

  2003cited by this paper
• Comparative Analysis of an Improved Thioflavin-S Stain, Gallyas Silver Stain, and Immunohistochemistry for Neurofibrillary Tangle Demonstration on the Same Sections

  2002cited by this paper
• Tau‐66: evidence for a novel tau conformation in Alzheimer's disease

  2001cited by this paper
• Tissue shrinkage and unbiased stereological estimation of particle number and size *

  2001cited by this paper
• C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

  2000cited by this paper
• Tau protein and the paired helical filament of Alzheimer's disease.

  1999cited by this paper
• Tau Cleavage and Dephosphorylation in Cerebellar Granule Neurons Undergoing Apoptosis

  1998cited by this paper
• Truncated tau protein as a new marker for Alzheimer's disease.

  1994cited by this paper
• Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament.

  1993cited by this paper
• Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51.

  1991cited by this paper
• A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

  1991cited by this paper
• A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

  1990influential reference
• Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

  1989cited by this paper
• Characterisation of the first monoclonal antibody against the pronase resistant core of the Alzheimer PHF.

  1989cited by this paper
• Structural characterization of the core of the paired helical filament of Alzheimer disease.

  1988cited by this paper
• The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis

  1988cited by this paper
• Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease.

  1988cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology

  1987cited by this paper
• Reversible assembly purification of microtubules without assembly-promoting agents and further purification of tubulin, microtubule-associated proteins, and MAP fragments.

  1986cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Silver staining of Alzheimer's neurofibrillary changes by means of physical development.

  1971cited by this paper

• Understanding Tau pathology: Insights from animal models

  2025cites this paper
• Illuminating Tau Aggregates: Multiscale Approaches for Detection, Imaging, and Understanding

  2025cites this paper
• PET Imaging of a Transgenic Tau Rat Model SHR24 with [18F]AV1451

  2025cites this paper
• Associations Between Diabetes Mellitus and Neurodegenerative Diseases

  2025cites this paper
• Novel strategies for targeting tau oligomers in neurodegenerative diseases

  2025cites this paper
• Telomere-driven senescence accelerates tau pathology, neuroinflammation and neurodegeneration in a tauopathy mouse model

  2025cites this paper
• Severe neurodegeneration in brains of transgenic rats producing human tau prions

  2024cites this paper
• Inflammatory cytokines, oxidative stress, and tau protein impairment in cognitive functioning in patients with diabetes mellitus

  2024cites this paper
• Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models

  2024cites this paper
• Astrocytic tau inclusions lead to microglial abnormalities, but leave neuronal networks intact

  2024cites this paper
• Methods for Biochemical Isolation of Insoluble Tau in Rodent Models of Tauopathies.

  2024cites this paper
• Updates in Alzheimer's disease: from basic research to diagnosis and therapies

  2024cites this paper
• FTLD-MAPT mutations and short 5′UTR Tau mRNAs increase Tau translation

  2024cites this paper
• Toward an animal model of Progressive Supranuclear Palsy

  2024cites this paper
• Advancements and Challenges in Preclinical Study Models of Neurodegenerative Brain Diseases: Alzheimer's and Parkinson's Diseases

  2024cites this paper
• Tau protein profiling in tauopathies: a human brain study

  2024cites this paper
• Peripheral Mitochondrial Dysfunction: A Potential Contributor to the Development of Metabolic Disorders and Alzheimer’s Disease

  2023cites this paper
• De novo design of a β-helix tau protein scaffold: An oligomer-selective vaccine immunogen candidate for Alzheimer’s disease

  2023cites this paper
• Pathological Impact of Tau Proteolytical Process on Neuronal and Mitochondrial Function: a Crucial Role in Alzheimer’s Disease

  2023cites this paper
• The unique neuropathological vulnerability of the human brain to aging.

  2023cites this paper
• Can accelerated ageing models inform us on age‐related tauopathies?

  2023cites this paper
• Tau truncation in the pathogenesis of Alzheimer’s disease: a narrative review

  2023influential citation
• Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy.

  2023cites this paper
• Dose-dependent Phosphorylation of Endogenous Tau by Intermittent Hypoxia in Rat Brain.

  2022cites this paper
• Tau as a Biomarker of Neurodegeneration

  2022cites this paper
• Enriched environment ameliorates propagation of tau pathology and improves cognition in rat model of tauopathy

  2022cites this paper
• The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.

  2022cites this paper
• Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.

  2022cites this paper
• Interaction kinetics reveal distinct properties of conformational ensembles of three‐repeat and four‐repeat tau proteins

  2022cites this paper
• Targeted UHPLC-ESI-MS/MS Analysis of Selected Neurotransmitters, Tryptophan and Its Metabolite Kynurenine in Tau Transgenic Rat Brain Tissue: A Pivotal Study

  2022cites this paper
• Controlled tau cleavage in cells reveals abnormal localizations of tau fragments.

  2022cites this paper
• Do tau-synaptic long-term depression interactions in the hippocampus play a pivotal role in the progression of Alzheimer’s disease?

  2022cites this paper
• Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey

  2022cites this paper
• Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies

  2022cites this paper
• Linking Diabetes to Alzheimer’s Disease: Potential Roles of Glucose Metabolism and Alpha-Glucosidase

  2022cites this paper
• Astrocytes Derived from Familial and Sporadic Alzheimer’s Disease iPSCs Show Altered Calcium Signaling and Respond Differently to Misfolded Protein Tau

  2022cites this paper
• Semantic processing and neurobiology in Alzheimer's disease and Mild Cognitive Impairment.

  2022cites this paper
• The Disease Associated Tau35 Fragment has an Increased Propensity to Aggregate Compared to Full-Length Tau

  2021cites this paper
• Tau Seeding Mouse Models with Patient Brain-Derived Aggregates

  2021cites this paper
• Murine models of tauopathies

  2021cites this paper
• Metabolic Syndrome: Is It Time to Add the Central Nervous System?

  2021cites this paper
• A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer’s disease

  2021cites this paper
• Alzheimer’s disease brain contains tau fractions with differential prion-like activities

  2021cites this paper
• Generation and Role of Calpain-Cleaved 17-kDa Tau Fragment in Acute Ischemic Stroke

  2021cites this paper
• Type 2 Diabetes Mellitus Easily Develops into Alzheimer’s Disease via Hyperglycemia and Insulin Resistance

  2021cites this paper
• Editorial: Tau Pathology in Neurological Disorders

  2021cites this paper
• WIN55,212-2 Attenuates Cognitive Impairments in AlCl3 + d-Galactose-Induced Alzheimer’s Disease Rats by Enhancing Neurogenesis and Reversing Oxidative Stress

  2021cites this paper
• Recent progresses on p-tau as a blood-based Alzheimer’s disease biomarker

  2021cites this paper
• Non-Rodent Genetic Animal Models for Studying Tauopathy: Review of Drosophila, Zebrafish, and C. elegans Models

  2021cites this paper
• Tau Oligomers Neurotoxicity

  2021cites this paper
• Key Mechanisms and Potential Implications of Hericium erinaceus in NLRP3 Inflammasome Activation by Reactive Oxygen Species during Alzheimer’s Disease

  2021cites this paper
• Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies

  2021cites this paper
• Viral Delivery of Non-Mutated Human Truncated Tau to Neurons Recapitulates Key Features of Human Tauopathy in Wild-Type Mice

  2020cites this paper
• Truncation of Tau selectively facilitates its pathological activities

  2020cites this paper
• Tau in Alzheimer’s Disease: Pathological Alterations and an Attractive Therapeutic Target

  2020cites this paper
• The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?

  2020cites this paper
• Exploring the Potential of Neuroproteomics in Alzheimer's Disease.

  2020cites this paper
• Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy

  2020cites this paper
• Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine.

  2020cites this paper
• Two new acylated triterpenoidal saponins from Gleditsia caspica Desf. and the effect of its saponin content on LPS-induced cognitive impairment in mice

  2020cites this paper
• Tau Protein and Its Role in Blood–Brain Barrier Dysfunction

  2020cites this paper
• Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases – ERRATUM

  2020cites this paper
• Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases

  2020cites this paper
• Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models

  2020cites this paper
• Environmental Enrichment Rescues Functional Deficit and Alters Neuroinflammation in a Transgenic Model of Tauopathy

  2020cites this paper
• Physiological tau interactome in brain and its link to tauopathies.

  2020cites this paper
• Peroxisomal Dysfunction in Neurological Diseases and Brain Aging

  2020cites this paper
• Aging lowers PEX5 levels in cortical neurons in male and female mouse brains.

  2020cites this paper
• Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy

  2020cites this paper
• Asparagine residue 368 is involved in Alzheimer's disease tau strain–specific aggregation

  2020cites this paper
• Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies

  2019cites this paper
• Pathological Alterations of Tau in Alzheimer’s Disease and 3xTg-AD Mouse Brains

  2019cites this paper
• A walk through tau therapeutic strategies

  2019cites this paper
• Molecular mechanisms of cellular dysfunction caused by a tauopathy-associated fragment

  2019cites this paper
• Mechanistic Insight into Tau Fibril Cross-Seeding Barriers: Structural Order and Disorder

  2019cites this paper
• Intersection of pathological tau and microglia at the synapse

  2019cites this paper
• Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies.

  2019cites this paper
• Diabetes as a risk factor for Alzheimer’s disease in the Middle East and its shared pathological mediators

  2019cites this paper
• MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer's disease.

  2019cites this paper
• Genetic Background Influences the Propagation of Tau Pathology in Transgenic Rodent Models of Tauopathy

  2019cites this paper
• Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy

  2019cites this paper
• Experimental Models in Neurodegenerative Diseases

  2019cites this paper
• Rederivation of transgenic rodent models expressing disease modified tau protein-a report

  2019influential citation
• AADvac1, an Active Immunotherapy for Alzheimer’s Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development

  2018cites this paper
• Seeding Properties of Amyloid-beta and Tau in the Cerebrospinal Fluid

  2018cites this paper
• Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles

  2018cites this paper
• Caractérisation d'anticorps à domaine unique dirigés contre la protéine Tau

  2018cites this paper
• Ectopic Expression Induces Abnormal Somatodendritic Distribution of Tau in the Mouse Brain

  2018cites this paper
• Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead

  2018cites this paper
• Differential Hyperphosphorylation of Tau-S199, -T231 and -S396 in Organotypic Brain Slices of Alzheimer Mice. A Model to Study Early Tau Hyperphosphorylation Using Okadaic Acid

  2018cites this paper
• Neurodegenerative disease mechanisms induced by tau fragmentation in a novel model of human tauopathy

  2018cites this paper
• Pathological Changes of Tau Related to Alzheimer's Disease.

  2018cites this paper
• Inhibitory interneurons in Alzheimer's disease.

  2018cites this paper
• Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits

  2018cites this paper
• Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia

  2018cites this paper
• FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

  2018cites this paper
• Rodent models for Alzheimer disease

  2018cites this paper
• Current state of tau aggregation inhibitors

  2018cites this paper
• Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation

  2018cites this paper
• d-galactose and aluminium chloride induced rat model with cognitive impairments.

  2018cites this paper